HS-20089

DRUG3 trials

Sponsors

Hansoh BioMedical R&D Company

Conditions

Advanced Solid TumorsEndometrial CancerFallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer

Phase 1

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

RecruitingNCT06336707

Hansoh BioMedical R&D CompanyAdvanced Solid Tumors

Start: 2024-04-11End: 2028-04-08Target: 1048Updated: 2024-07-18

Phase 2

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

RecruitingNCT06014190

Hansoh BioMedical R&D CompanyEndometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer +1

Start: 2023-12-18End: 2027-12-31Target: 460Updated: 2024-08-29

Phase 3

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

RecruitingNCT06855069

Hansoh BioMedical R&D CompanyOvarian Cancer

Start: 2025-03-13End: 2029-03-07Target: 468Updated: 2025-12-17